Effect of ResvidaTM on fat oxidation and mitochondrial biogenesis in healthy obese subjects

Completed

Conditions: impaired fat oxidation
impaired lipid catabolism
10013317

Registration Number: NL-OMON35600

Lead Sponsor: niversiteit Maastricht

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 18

Inclusion Criteria

* Male sex
* Age 45-65 years
* Body fat percentage > 25, BMI 30-35 kg/m2
* Sedentary
* Stable dietary habits
* Willingness to abstain from ingestion of resveratrol-containing foods
* Healthy

Exclusion Criteria

* Female sex
* Unstable body weight (weight gain or loss > 3 kg in the last three months)
* Total body fat (%) < 25%
* Fasting plasma glucose > 6.1 mmol/l
HB < 7.8 mmol/l
* Engagement in programmed exercise > 2 hours total per week
* Impaired kidney and/ or hepatic function
* First- or second-degree family member with type 2 diabetes mellitus
* Any medical condition requiring treatment and/or medication use
* Intake of dietary supplements except vitamins and minerals
* Unwilling to restrict high-resveratrol-containing foods
* Current alcohol consumption > 20 grams/day
* Participation in another biomedical study within 1 month before the first screening visit
* A contraindication to MRI scanning. These contra-indications include patients with the following devices:
o Central nervous system aneurysm clips
o Implanted neural stimulator
o Implanted cardiac pacemaker of defibrillator
o Cochlear implant
o Insulin pump
o metal containing corpora aliena in the eye or brains

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary outcome parameter is the difference in mitochondrial number,<br /><br>intrinsic function and fat oxidative capacity after a 4 week treatment with<br /><br>ResvidaTM compared to the placebo trial.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary endpoints are the differences in skeletal muscle and liver lipid<br /><br>content, and lipolysis in skeletal muscle and adipose tissue after 4 weeks<br /><br>ResvidaTM or placebo supplementation.</p><br>